AB0310 TROUGH CONCENTRATION AND ESTIMATED CLEARANCE CAN DETECT IMMUNOGENICITY TO ADALIMUMAB IN RA PATIENTS: A PROSPECTIVE LONGITUDINAL MULTICENTRE STUDY
Authors: D. Ternant, J. Elhasnaoui, N. Szely, S. Hacein-Bey, A. Gleizes, C. Richez, J. Manson, M. Soubrier, O. Brocq, J. Avouac, A. Fogdell-Hahn, P. Dönnes, G. Paintaud, C. Desvignes, F. Deisenhammer, S. Spindeldreher, M. Pallardy, X. Mariette, D. Mulleman
Journal: Annals of the Rheumatic Diseases (2020)

Background: Anti-Drug Antibodies (ADA) to adalimumab increase drug clearance in rheumatoid arthritis (RA). Objectives: To study the ability of drug concentration or estimating clearance to identify ADA to adalimumab. Methods: Adalimumab concentration was measured with a validated ELISA. ADA was measured using a capture ELISA (Theradiag®) and the Meso scale discovery (MSD) platform. Using a bayesian PK model, adalimumab clearance was estimated at 1, 3, 6 and 12 months. Predictions for ADA presence were calculated, and the correlation between ADA and adalimumab clearance was analysed. Results: We analyzed 108 samples from 53 RA patients. Serum concentrations and clearance estimates showed good prediction performance for ADA presence (Table 1). There was a correlation between adalimumab clearance and ADA (Figure 1). Table 1. Immunogenicity prediction of adalimumab, using trough concentration or estimated clearance Time of visit ADA method Adalimumab trough concentration Adalimumab estimated clearance AUC ROC p-value AUC ROC p-value Month 1 THER .55 .6411 .52 .8358 MSD .65 .0821 .61 .1872 Month 3 THER .89 .0006 .91 .0003 MSD .73 .0096 .72 .0131 Month 6 THER .95 .0035 .95 .0035 MSD .85 .0004 .84 .0006 Month 12 THER .87 .0045 .86 .0057 MSD .88 .0002 .88 .0002 Figure 1. correlation between adalimumab estimated clearance and ADA as provided by the Meso scale discovery (MSD) plateform Conclusion: Adalimumab concentration and clearance should be considered as reliable predictors for ADA presence in RA patients. Acknowledgments: Measurement of adalimumab serum concentrations was performed within the ‘Centre pilote de suivi biologique des anticorps thérapeutiques’ (CePiBAc)– Pilot centre for therapeutic antibodies monitoring platform of Tours University Hospital, which was cofinanced by the European Regional Development Fund (ERDF). We thank Oscar Knight, Delphine Delord and Fabien Giannoni (ABIRISK lab technician), Caroline Brochon and Anne Claire Duveau (CePIBAc), Aliette Decock-Giraudaud (Centre de ressource-Biobank), Sophie Tourdot (ABRISIK Project manager), Aline Doublet (Assistance Publique Hopitaux de Paris, Agnès Hincelin-Méry (Sanofi, Chilly-Mazarin, France). This work has received support from the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement no. 115303, the resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contributions. Disclosure of Interests: David Ternant Consultant of: Sanofi and Amgen., Jamal Elhasnaoui: None declared, Natacha Szely: None declared, Salima Hacein-Bey: None declared, Aude Gleizes: None declared, Christophe Richez Consultant of: Abbvie, Amgen, Mylan, Pfizer, Sandoz and UCB., Jessica Manson: None declared, Martin SOUBRIER: None declared, Olilvier Brocq: None declared, Jérôme Avouac: None declared, Anna Fogdell-Hahn Grant/research support from: Biogen Idec and Pfizer., Consultant of: Pfizer, Biogen, Merck-Serono, and Sanofi-Genzyme., Pierre Dönnes: None declared, Gilles Paintaud Grant/research support from: Amgen, Genzyme (Sanofi), Lilly, Merck, Novartis, and Roche Pharma., Consultant of: Chugai, Novartis and Shire (Takeda), with remunerations received by his institution., Céline Desvignes: None declared, Florian Deisenhammer: None declared, Sebastian Spindeldreher Employee of: Novartis, Marc Pallardy: None declared, Xavier Mariette Consultant of: BMS, Gilead, Medimmune, Novartis, Pfizer, Servier, UCB, Denis Mulleman Grant/research support from: Non-governmental organisation Lions Club Tours Val de France, French Society for Rheumatology., Consultant of: Pfizer, Novartis.